218 related articles for article (PubMed ID: 32850425)
1. Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer From the US and Chinese Perspectives.
Wu Q; Liao W; Zhang M; Huang J; Zhang P; Li Q
Front Oncol; 2020; 10():1336. PubMed ID: 32850425
[No Abstract] [Full Text] [Related]
2. Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis.
Dong L; Lin S; Zhong L; Nian D; Li Y; Wang R; Zhou W; Weng X; Xu X
Clin Breast Cancer; 2022 Jan; 22(1):e21-e29. PubMed ID: 34238670
[TBL] [Abstract][Full Text] [Related]
3. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Curigliano G; Mueller V; Borges V; Hamilton E; Hurvitz S; Loi S; Murthy R; Okines A; Paplomata E; Cameron D; Carey LA; Gelmon K; Hortobagyi GN; Krop I; Loibl S; Pegram M; Slamon D; Ramos J; Feng W; Winer E
Ann Oncol; 2022 Mar; 33(3):321-329. PubMed ID: 34954044
[TBL] [Abstract][Full Text] [Related]
4. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
Mueller V; Wardley A; Paplomata E; Hamilton E; Zelnak A; Fehrenbacher L; Jakobsen E; Curtit E; Boyle F; Harder Brix E; Brenner A; Crouzet L; Ferrario C; Muñoz-Mateu M; Arkenau HT; Iqbal N; Aithal S; Block M; Cold S; Cancel M; Hahn O; Poosarla T; Stringer-Reasor E; Colleoni M; Cameron D; Curigliano G; Siadak M; DeBusk K; Ramos J; Feng W; Gelmon K
Eur J Cancer; 2021 Aug; 153():223-233. PubMed ID: 34214937
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
Le QA; Bae YH; Kang JH
Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
[TBL] [Abstract][Full Text] [Related]
9. The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis.
Antonazzo IC; Cortesi PA; Miceli Sopo G; Mazzaglia G; Conte P; Mantovani LG
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831518
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China.
Zhang H; Zhang Y; Huang C; Wang J
Clin Drug Investig; 2021 Jun; 41(6):569-577. PubMed ID: 33876415
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Durkee BY; Qian Y; Pollom EL; King MT; Dudley SA; Shaffer JL; Chang DT; Gibbs IC; Goldhaber-Fiebert JD; Horst KC
J Clin Oncol; 2016 Mar; 34(9):902-9. PubMed ID: 26351332
[TBL] [Abstract][Full Text] [Related]
13. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
14. Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis.
Wu Y; Dong Z; Wang J; Fang Q
BMJ Open; 2022 Nov; 12(11):e065299. PubMed ID: 36379662
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
Yang J; Han J; Zhang Y; Muhetaer M; Chen N; Yan X
Front Pharmacol; 2022; 13():924126. PubMed ID: 36160459
[No Abstract] [Full Text] [Related]
16. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States.
Mudumba R; Chan HH; Cheng YY; Wang CC; Correia L; Ballreich J; Levy J
Value Health; 2024 Feb; 27(2):153-163. PubMed ID: 38042333
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China.
Liao M; Jiang Q; Hu H; Han J; She L; Yao L; Ding D; Huang J
J Med Econ; 2019 Jun; 22(6):584-592. PubMed ID: 30808230
[No Abstract] [Full Text] [Related]
18. Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China.
Tang Z; Xu X; Gao J; Chen L; Zhu Q; Wang J; Yan X; Chen B; Zhu Y
Front Public Health; 2022; 10():942767. PubMed ID: 36159262
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.
Shi D; Liang X; Li Y; Chen L
PLoS One; 2023; 18(8):e0290507. PubMed ID: 37616309
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
